InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Phase 3 Trial Network to 18 Sites for CYB003 in Depression
April 23, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced the expansion of its strategic partnership agreements to include 18 U.S. clinical sites for its multinational Phase 3 trial of CYB003, a next-generation psychedelic-based therapy for major depressive disorder (MDD). The APPROACH study, part of Cybin’s PARADIGM program, is expected to grow to approximately 45 sites. By leveraging […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Forms Strategic Partnership With Osmind to Prepare for Mental Health Drug Commercialization
April 21, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company, has entered a strategic partnership with Osmind, a technology and services provider with a network of over 800 U.S. psychiatry clinics. The collaboration aims to lay the groundwork for the commercialization of Cybin’s clinical programs CYB003, in Phase 3 for major depressive disorder, and CYB004, […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Final Preclinical Study for PTSD Treatment SPC-15
March 26, 2025
Silo Pharma (NASDAQ: SILO) announced the first dosing in a GLP-compliant toxicology and toxicokinetics study for its lead candidate, SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD). The study, part of an IND-enabling program, follows a pre-IND meeting with the FDA that aligned the company on the 505(b)(2) regulatory pathway, which may expedite approval […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures USPTO Patent for PTSD Treatment SPC-15
February 27, 2025
Silo Pharma (NASDAQ: SILO), a biopharmaceutical company developing novel therapeutics and drug delivery systems, announced that the U.S. Patent and Trademark Office (USPTO) has issued an Issue Notification for its patent application (No. 17/954,864), titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” The patent, which is set to be issued on March 4, 2025, […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Provisional Patent for SPC-15 Dual-Action Treatment
February 18, 2025
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, has filed a provisional patent application with the U.S. Patent and Trademark Office for its lead asset, SPC-15. The patent covers a dual-action method targeting stress-induced psychiatric behaviors through a combination of a serotonin type IV receptor agonist and an N-methyl-D-aspartate receptor antagonist. CEO Eric Weisblum emphasized […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Early Data on SP-26 Ketamine Implant Study
February 11, 2025
Silo Pharma (NASDAQ: SILO) announced encouraging early results from its ongoing study evaluating the pharmacokinetics, safety and tolerability of its SP-26 ketamine extended-release implant for chronic pain and fibromyalgia. The non-GLP study, launched in December 2024, marks the first small animal testing of SP-26, with dosing completed in early January. No serious side effects or […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports Q3 Financials, Advances Clinical Programs
February 11, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced third-quarter financial results and recent developments in its neuropsychiatry pipeline. The company continues advancing its lead programs, including CYB003, which has entered a multinational Phase 3 trial for major depressive disorder, and CYB004, now in Phase 2 testing for generalized anxiety disorder. Financially, Cybin reported a net loss of […]
AI Alliance in Europe Announces LLM to Rival DeepSeek and Silicon Valley
February 3, 2025
As the AI dominance of Silicon Valley comes under attack from upstarts like DeepSeek, an alliance in Europe is planning to up the ante with its ambition to come up with European-grown alternatives that are as good as or even better than the existing artificial intelligence options. The project, dubbed OpenEuroLLM, aims to develop next-gen […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Bolsters Intellectual Property with New Patent Filing for PTSD Treatment
January 22, 2025
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, has filed a provisional patent application with the U.S. Patent and Trademark Office (“USPTO”) for its lead asset SPC-15, demonstrating its commitment to innovative treatments for stress-induced psychiatric disorders, including post-traumatic stress disorder (“PTSD”). The patent focuses on targeting N-methyl-D-aspartate receptors (“NMDARs”) and serotonin type IV receptors […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Launches Strategic Partnership Program with Segal Trials for Phase 3 MDD Study
January 15, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a neuropsychiatry platform company, announced its first strategic partnership agreement (“SPA”) with Segal Trials as part of its multinational pivotal Phase 3 program for CYB003, targeting Major Depressive Disorder (“MDD”). Segal Trials, a South Florida-based research network specializing in psychiatry and psychedelics, joins Cybin in advancing its Phase 3 […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights 2024 Achievements and Outlines Key 2025 Milestones
January 13, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company, summarized its 2024 accomplishments and detailed upcoming 2025 milestones. CEO Doug Drysdale highlighted advancements in its pipeline of tryptamine serotonin receptor agonists, including CYB003, a deuterated psilocin program for major depressive disorder (“MDD”), and CYB004, a deuterated dimethyltryptamine in intramuscular form for generalized anxiety disorder […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Lytham Partners Healthcare Summit
January 10, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company, announced that CEO Doug Drysdale will join a fireside chat at the virtual Lytham Partners 2025 Investor Healthcare Summit on Jan. 13. The live webcast begins at 11:30 a.m. ET, with an archived version accessible afterward on the company’s investor relations site. To view the […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Strengthens Patent Portfolio with Approval for PTSD Treatment SPC-15
January 8, 2025
Silo Pharma (NASDAQ: SILO) received a Notice of Allowance from the U.S. Patent and Trademark Office for a key patent supporting its lead asset, SPC-15, an intranasal treatment for PTSD. The patent, expected to be formally issued within 90 days, builds on Silo’s existing intellectual property and expands protection for SPC-15, a serotonin 5-HT4 receptor […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Highlights Progress in Mental Health and Chronic Pain Treatments
January 2, 2025
Silo Pharma (NASDAQ: SILO), a biopharmaceutical company specializing in innovative drug formulations and delivery systems, issued a shareholder letter outlining advancements for its leading assets, SPC-15 and SP-26. SPC-15, an intranasal treatment for PTSD and stress-induced anxiety, is progressing toward FDA submission in 2025, supported by promising preclinical results for PTSD, eating disorders, and depression. […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances Ketamine Implant Development with Pharmacokinetic Study
December 18, 2024
Silo Pharma (NASDAQ: SILO), a biopharmaceutical company developing innovative therapeutics, has initiated a pharmacokinetic (“PK”) and tolerability study for its dissolvable ketamine-based implant, SP-26, in collaboration with AmplifyBio. The study will evaluate SP-26, aimed at treating chronic pain and fibromyalgia, in a minipig model over three weeks, focusing on absorption, distribution, metabolism, and excretion (“ADME”). […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights Promising Advances in Depression and Anxiety Treatment at ACNP Annual Meeting
December 10, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) presented compelling data from its clinical programs at the American College of Neuropsychopharmacology (“ACNP”) Annual Meeting, including 12-month efficacy results from its Phase 2 study of CYB003, a deuterated psilocin program for Major Depressive Disorder (“MDD”), which demonstrated a 100% response rate and 71% remission rate after two doses. […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Water Tower Research Fireside Chat
December 4, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options. The company has announced that its CEO Doug Drysdale and CMO Amir Inamdar, MBBS, DNB (Psych), FFPM will participate in the Water Tower Research Fireside Chat Series taking place […]
HUB Cyber Security Reports First Half 2024 Financial Results and Corporate Update
December 2, 2024
TEL AVIV, Israel, Dec. 02, 2024 (GLOBE NEWSWIRE) — via IBN – HUB Cyber Security Ltd. (NASDAQ: HUBC) (“HUB”; or the “Company”), a leading provider of cybersecurity solutions and advanced data fabric, today announced its financial results for the first half of 2024. Financial results for H1 2024: Noah Hershcoviz, CEO of HUB Security, said, […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partners with Kymanox to Advance Ketamine Implant Therapeutic for Chronic Pain
December 2, 2024
Silo Pharma (NASDAQ: SILO) has entered into a collaboration with Kymanox to develop a subcutaneous insertion device for SP-26, its ketamine-loaded implant designed to treat fibromyalgia and chronic pain. The partnership will begin with proof-of-concept design, followed by prototype and feasibility testing to optimize insertion depth. Silo CEO Eric Weisblum highlighted the progress in developing […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Promising Preclinical Results for SPC-15 in Treating Severe Psychiatric Disorders
November 18, 2024
Silo Pharma (NASDAQ: SILO) announced encouraging preclinical study results for SPC-15, a novel dual-target therapy combining a serotonin 5-HT4 receptor agonist and an NMDA receptor antagonist. The treatment demonstrated superior efficacy in reducing stress-induced behaviors in animal models compared to single-agent therapies, highlighting its potential for managing major depressive disorder and other severe stress-related conditions. […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports Sustained 12-Month Efficacy for CYB003 in Treating Major Depressive Disorder
November 18, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) shared promising 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated psilocin treatment for major depressive disorder (“MDD”). Participants receiving two 16 mg doses of CYB003, three weeks apart, achieved a 100% response rate and 71% remission rate at the 12-month mark, with an average […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present Key 12-Month Data and Phase 3 Program Insights for CYB003 in Upcoming Webcast
November 14, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) announced it will hold a conference call and webcast on Nov. 18, 2024, at 8 a.m. ET, led by CEO Doug Drysdale and CMO Amir Inamdar. The event will cover 12-month efficacy and safety results from its Phase 2 study of CYB003 for Major Depressive Disorder, along with an […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Begins Phase 3 Trials of CYB003 for Depression, Building on Promising Phase 2 Results
November 13, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) has initiated its Phase 3 PARADIGM program to evaluate the efficacy and safety of CYB003, an adjunctive treatment for Major Depressive Disorder (MDD). PARADIGM includes three pivotal studies: APPROACH, EMBRACE, and EXTEND, each aimed at examining CYB003’s potential to deliver rapid and durable relief from depressive symptoms. In Phase 2, […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Promising Results from Testing of Ketamine-Loaded Implant for Chronic Pain Relief
October 31, 2024
Silo Pharma (NASDAQ: SILO), a biopharmaceutical company developing innovative treatments, announced promising results from recent tests on its SP-26 ketamine-loaded implant for fibromyalgia and chronic pain. Conducted with Sever Pharma Solutions, the sterilization and dissolution tests showed a sustained drug release of over 80% across seven days, demonstrating the implant’s consistent, time-controlled formulation. The tests […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present Advancements in Mental Health Treatment at Milken Institute Summit
October 31, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will join a panel titled “The Next Frontier in Mental Health Research” at the 2024 Milken Institute Future of Health Summit in Washington, D.C., on November 13. Drysdale will discuss Cybin’s progress in developing breakthrough treatments for mental health conditions, including CYB003, a Phase […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Granted Patent for Lead Candidates in CYB005 Program
October 24, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that the United States Patent and Trademark Office has granted U.S. patent 12,122,741 for the composition of matter related to lead preclinical candidates in its CYB005 phenethylamines program. This patent supports Cybin’s development of non-hallucinogenic treatments for Central Nervous System (“CNS”) disorders. Cybin is focused on expanding its […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in Upcoming Water Tower Research Fireside Chat
October 3, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced participation in the Water Tower Research Fireside Chat Series on Tuesday, October 8, 2024, at 3 p.m. ET. Cybin CEO Doug Drysdale will join the fireside chat hosted by Robert Sassoon, Senior Research Analyst […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Strengthens Its Clinical Development Team
October 1, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced the appointment of talented and experienced industry leaders to its clinical and R&D team. The company welcomed Dr. Mirza Rahman, M.D., M.P.H., FACPM, as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Chief Medical Officer to Participate in a Panel Discussion at Upcoming Summit
September 24, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced that it will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit to be held virtually on Thursday, September 26, 2024. The company’s Chief Medical Officer, Amir Inamdar, will be part […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports on Status of Key Clinical Milestones
September 20, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, has provided an update on corporate accomplishments and clinical milestones. According to the announcement, the company is planning to begin a pivotal CYB003 phase 3 study in major depressive disorder (“MDD”) […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Completes 38-for-1 Share Consolidation
September 19, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced that it has completed the previously announced consolidation of its issued and outstanding common shares. Trading of the common shares reflecting the consolidation commenced at the opening of trading on Thursday morning. According to […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports on FDA Pre-IND Meeting to Advance Development of Lead Program
September 10, 2024
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has completed a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”). The meeting focused on the company’s development plan for SPC-15, an intranasal prophylactic treatment for post-traumatic stress […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
September 4, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options. The company today announced that its CEO, Doug Drysdale, will participate in a fireside chat and panel discussion at the H.C. Wainwright 26th Annual Global Investment Conference. The event will be held September 9-11, 2024, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Annual and Special Meeting of Shareholders, Share Consolidation
August 28, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is releasing the report of its annual and special meeting of shareholders. Held on Aug. 27, 2024, the meeting included 87 shareholders, attending in person or by proxy; those persons […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO), Sever Pharma Expand Existing Agreement to Include Extrusion of Novel Ketamine Implant Therapeutic
August 15, 2024
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has entered a new agreement with Sever Pharma Solutions. According to the announcement, the agreement is regarding scale-up extrusion of Silo’s SP-26 dissolvable, ketamine-based, injectable implant designed for the treatment of fibromyalgia and […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Holds Initial Breakthrough Therapy Meeting with FDA, Plans for CYB003 Phase 3 Trial
August 13, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, met with the U.S. Food and Drug Administration (“FDA”) to hold a Type B Initial Breakthrough Therapy Meeting. The meeting, which was held last week, was regarding the company’s plans […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases Q1 2025 Financial Results, Business Highlights
August 8, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today reported unaudited financial results for its first quarter of fiscal 2025 ended June 30, 2024 (“Q1 2025”) and provided recent business highlights. In the report, the company noted continued progress towards initiating its Phase 3 […]
InvestorNewsBreaks – Iteris Inc. (NASDAQ: ITI) Selected by City of Lakeland to Enhance Road User Safety, Security
August 7, 2024
Iteris (NASDAQ: ITI), the world’s trusted technology ecosystem for smart mobility infrastructure management, today announced that the City of Lakeland, Florida, has selected it to provide smart mobility infrastructure management technologies to support the city’s Intersection Crash Avoidance Safety Program (“iCASP”). The project includes the deployment of key components of Iteris’ ClearMobility(R) Platform, the world’s […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters Agreement to Launch New Study of SPU-16 Homing Peptide for Multiple Sclerosis
August 7, 2024
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has entered into an agreement with WuXi AppTec (Hong Kong) Limited, a leading global contract research organization (“CRO”). The agreement regards the launch of a preclinical small animal study of SPU-16, a central […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in a Fireside Chat at Upcoming Conference
August 7, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced that its CEO, Doug Drysdale, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024, at 2 p.m. ET. Mr. Drysdale’s fireside chat will be […]